Objective This study aimed to evaluate the prevalence and predictors of cardiovascular disease (CVD), chronic kidney disease ...

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...

The FDA has approved narsoplimab (Yartemlea) as the first treatment for hematopoietic stem cell transplant (HSCT)-associated ...

For most, getting into a car is a task that can be done without assistance. Yet for those whose destination is the moon, the ...

Also called C3G, this rare kidney disease often affects children and young adults, but it can happen at any age. It has a major impact on a person’s health and life. C3G has two forms: dense deposit ...

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...

A new study offers hope for brain cancer patients facing memory loss from radiotherapy. By blocking a single immune receptor, scientists preserved cognition in mice without dulling the cancer-killing ...

Treatment with cemdisiran was associated with a statistically significant improvement in MG-ADL total score compared with placebo. Topline results were announced from a phase 3 trial evaluating ...

Your peripheral nervous system (PNS) is crucial to navigating daily life. It lets you walk, controls your eye movements, and rings your brain’s alarms when you step on a Lego brick. Yet researchers ...

A Regeneron Pharmaceuticals drug that lowers levels of a disease-driving protein has met the goals of a pivotal test in the rare disease generalized myasthenia gravis. Based on these results, ...